LEO Pharma Buys Worldwide Dersimelagon Rights for up to $435 Million

LEO Pharma buys worldwide dersimelagon rights for up to $435 million

By Jesus Calero Aug 18 (Reuters) - Danish drugmaker LEO Pharma said on Tuesday it had agreed to acquire worldwide rights to drug ​candidate dersimelagon from Tanabe Pharma for up ‌to $435 million in up-front and near-term milestone payments. As LEO Pha...

Leo Pharma to license Tanabe’s rare disease drug for pain with sun exposure

Leo Pharma said it will pay Japan’s Tanabe Pharma up to $435 million in upfront and near-term payments to license an oral drug for a pair of genetic light-sensitive skin diseases. The Danish biotech will ...